Kazia Suffers Brain Cancer Drug Setback But All Hope Not Lost
Paxalisib Pulled From GBM Platform Study
Executive Summary
News that the Australian biotech's paxalisib did not meet pre-defined criteria to continue into the second stage of a major glioblastoma platform trial saw Kazia's stock crash, but investor reaction appears to be excessive.
You may also be interested in...
C4XD Delisting Highlights Funding Frustration For UK Biotechs
The Manchester-based group has had enough of being undervalued in the public markets and is going private again.
Novo Reaches Winning Post With Gamechanger Once-Weekly Insulin
The Danish drugmaker is cementing its leadership in diabetes with an imminent approval in Europe for Awiqli which reduces the number of basal insulin injections for patients from seven to just one per week.
Novo Pumps Up Heart Failure Prospects With Cardior Purchase
The Danish drugmaker is spending some of its semaglutide cash on a mid-stage RNA-based heart failure therapy developed by the German biotech.